Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Semi-anunal Business Results
February 9, 2004
- 30 NCEs Approved in January-November 2003: PFSB
February 9, 2004
- 3rd Qtr Business Results
February 9, 2004
- 70%-Multiple Rule to Be Used in Initial NHI Listing for Generics
February 9, 2004
- PRESS SEMINAR
February 9, 2004
- 5 Deaths by Interstitial Pneumonia Linked to Aventis' Arava
February 9, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 9, 2004
- Nat'l Hospitals, Sanatoriums to Fully Pay Drug Costs: Health Minister
February 9, 2004
- GEYMS: World's Fastest Cardiovascular CT "e-Speed"
February 9, 2004
- Kuraya Sanseido Integrating Systems, Marketing Strategies Newly Start on Oct. 1
February 2, 2004
- BULLETIN
February 2, 2004
- FJPWA to Study Ways to Ensure Stable Profits for Wholesalers
February 2, 2004
- MEDICAL DEVICE NEWS IN BRIEF
February 2, 2004
- Biotech-related Market to Reach \1.1 Trillion in 2010: Fuji Keizai
February 2, 2004
- BULLETIN
February 2, 2004
- BUSINESS NEWS IN BRIEF
February 2, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 2, 2004
- Annual Business Results
February 2, 2004
- WORLD NEWS IN BRIEF
February 2, 2004
- NHI Price Reductions by Re-pricing Rule Unlikely This Year
February 2, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…